bit.bio, a Cambridge, UK-based biotechnology company specializing in human cell programming, has raised $25 million in Series D funding to expand its portfolio of human cell models and meet growing demand from pharmaceutical companies, biotechnology businesses, and research organizations. The financing follows the company’s Series C round earlier in 2026 and includes investments from existing backer M&G Investments and Dr. Jonathan Milner, founder and former CEO of Abcam.
The funding comes as bit.bio reports record demand for its human cell models, with paid vial volumes increasing 76% year to date in 2026. Orders increased 34%, while the number of active customers grew 40%, including a 63% increase in academic customers.
The company plans to use the additional capital to introduce new human cell types, expand access to its products, and strengthen its position as a supplier of standardized biological models for drug discovery and development.
bit.bio has developed a proprietary cell programming technology called opti-ox, which enables the production of defined human cell types with high levels of consistency and scalability. The platform is designed to address longstanding challenges associated with traditional cell models, including donor variability, inconsistent experimental results, and limited availability.
Its portfolio currently includes more than 50 human cell types, including models representing the heart, liver, and central nervous system. These products support applications in disease research, functional genomics, drug discovery, and toxicology.
The company’s expansion comes as the pharmaceutical industry increasingly explores human-relevant experimental models to improve the efficiency and accuracy of drug development.
Advances in artificial intelligence are accelerating the identification and design of potential therapeutic compounds, creating demand for reliable biological systems capable of evaluating how those compounds interact with human cells.
At the same time, growing interest in alternatives to animal testing is encouraging researchers to adopt models that more closely reflect human biology.
bit.bio aims to address both trends by providing reproducible human cell models that researchers can access at scale.
With its manufacturing infrastructure already established, the company is concentrating on expanding its product catalog and converting increased demand into sustained commercial growth.
The participation of M&G Investments reflects confidence in bit.bio’s ability to translate its technology into a larger global life sciences tools business. Milner’s involvement also brings experience in developing scientific research products for international markets.
Through the Series D financing, bit.bio intends to make standardized human cell models more widely available and support the development of research methods that improve the predictive value of preclinical testing.
KEY QUOTES:
“The industry is reaching an inflection point in drug discovery. AI is changing the speed at which new medicines can be discovered, while the move towards animal testing alternatives is creating growing demand for models that better reflect human biology. What these fundamental shifts have in common is the need for vast quantities of consistent human cell models. Someone needs to be able to supply those cells at scale and our investors believe bit.bio is the company capable of achieving that aim. This creates an enormous opportunity for bit.bio to step forward and address that need. We already have the technology and manufacturing capacity in place. Our focus now is on expanding the portfolio of cells we can offer and making them accessible to researchers around the world. This investment is a vote of confidence in our ability to become a major supplier of the human cells that the next generation of drug development will depend on.”
Dr. Emma Pepperell, CEO Of bit.bio
“M&G’s Crossover strategy is focused on backing ambitious businesses as they move into their next phase of commercial growth, and bit.bio is a strong example of that opportunity. It has proven technology, established manufacturing capability and growing demand from customers. As the way medicines are discovered and tested evolves, we see significant potential for bit.bio to scale globally and establish human cell models as an increasingly important part of life sciences research.”
Cornel Chiriac, Investment Director Of Crossover At M&G Investments
“I’ve spent much of my career building life sciences tools businesses, and I know what it takes to turn a powerful scientific idea into a company that can shape an industry. Abcam showed how a focused product offering can grow into a global business by becoming indispensable to researchers. I see bit.bio doing that for human cells. Biology is becoming increasingly central to how medicines are discovered and developed, but progress depends on having the right human cells, in the right quantities, with the consistency researchers can trust. That is a fundamental need, and it is only going to grow. bit.bio has the opportunity to build the cell platform that researchers worldwide turn to as a matter of course, and, in doing so, to create one of the defining life sciences tools businesses of its generation.”
Dr. Jonathan Milner, Founder And Former CEO Of Abcam

